GALECTIN THERAPEUTICS INC. Stock Split Ratio
GALECTIN THERAPEUTICS INC. (GALT) reported Stock Split Ratio of 16.67% for the 1-month period ending 2012-03-23, per its 10-Q filed 2014-05-13.
Discontinued › Notes › Equity › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2014-05-13
- 2012-03-23: Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month 16.67%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month |
|---|---|
| 2012-03-23 | 16.67% 10-Q · filed 2014-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |